Evidence map›Paper›PMID 39273079›Full record

ReviewCells2024

Potential Therapeutic Interventions Targeting NAD

Samuel Lundt, Shinghua Ding

Abstract readReview
In one paragraph

Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Metabolomic analyses of amyotrophic lateral sclerosis, muscle cramps, and TJ-68 treatment.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
  2. International journal of stem cells · 2026
    Article
  3. Review
  4. Article
  5. Roles of SIRT3 in aging and aging-related diseases.International journal of biological sciences · 2025
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Samuel LundtDalton Cardiovascular Research Center (DCRC), Columbia, MO 65203, USA.
Shinghua DingDalton Cardiovascular Research Center (DCRC), Columbia, MO 65203, USA.ORCID 0000-0002-7791-1342

Funding

The Role of Gliotransmission in Cerebral IschemiaR01NS069726 · NINDS · UNIVERSITY OF MISSOURI-COLUMBIA · PI DING, SHINGHUA · 2010 to 2022
$3.3M
Pathogenesis and motor neuron degeneration of a novel disease associated with a P158A mutation in NAMPTR01NS123023 · NINDS · UNIVERSITY OF MISSOURI-COLUMBIA · PI Shinghua Ding · 2022 to 2026
$2.3M
A novel therapeutic approach for Alzheimer Disease (AD)R21AG080715 · NIA · UNIVERSITY OF MISSOURI-COLUMBIA · PI DING, SHINGHUA · 2023 to 2023
$392k
NIA NIH HHS R21 AG080715NIA NIH HHS R21AG080715NINDS NIH HHS R01 NS069726NINDS NIH HHS R01NS069726NINDS NIH HHS R01 NS123023NINDS NIH HHS R01NS123023
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting both upper and lower motor neurons. While there have been many potential factors implicated for ALS development, such as oxidative stress and mitochondrial dysfunction, no exact mechanism has been determined at this time. Nicotinamide adenine dinucleotide (NAD

Indexed as

Amyotrophic Lateral SclerosisNADAnimalsDisease Models, AnimalHumansNADALSmotor neuronNAD+NADaseNMJ

Identifiers

PMID39273079
PMCPMC11394323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.